RxDoctor Payments Data

Lydie Hazan

Beverly Hills, CANPI 1215013446

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (50.5%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Eisai Inc. at 32.7% of the total. Reporting peaked in 2019 at $3,734 and has fallen 97.1% since, to $108 in 2023.

$3,870in general payments, 2019–2025

Across 24 payments — averaging $161.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eisai Inc.$1K
  • Amgen$1K
  • Celltrion, Inc.$1K
  • AstraZeneca$117
  • Sanofi Pasteur Inc.$108
  • Navidea Biopharmaceuticals, Inc.$100
  • plus $28 from 1 others
$2,280,074in research payments, 2019–2025

Across 193 payments — averaging $11,814 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Vanda Pharmaceuticals Inc.$571K
  • Eli Lilly$563K
  • Amgen$292K
  • Cepheid$284K
  • Rhythm Pharmaceuticals, Inc.$178K
  • Mitsubishi Tanabe Pharma Development America, Inc.$72K
  • plus $321K from 11 others

What the payments were for

  • Consulting fees$1,02326%
  • Travel & lodging$1,95450%
  • Food & beverage$89423%

General payments by program year

19
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Where these figures come from

Is this you, or does something look wrong? →